Immune escape pathways from the HBV core_18-27 CD8 T cell response are driven by individual HLA class I alleles.

ABSTRACT:

Background and aims

There is growing interest in T cell-based immune therapies for a functional cure of chronic HBV infection including check-point inhibition, T cell-targeted vaccines or TCR-grafted effector cells. All these approaches depend on recognition of HLA class I-presented viral peptides. The HBV core region 18-27 is an immunodominant target of CD8+ T cells and represents the prime target for T cell-based therapies. Here, a high-resolution analysis of the core_18-27 specific CD8+ T cell and the selected escape pathways was performed.

Methods

HLA class I typing and viral sequence analyses were performed for 464 patients with chronic HBV infection. HBV-specific CD8+ T-cell responses against the prototype and epitope variants were characterized by flow cytom

SUBMITTER: Walker A 

PROVIDER: S-EPMC9686862 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature